F10 and Stroke: The phase III ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) study compared rivaroxaban (20 mg od; 15 mg od in patients with CrCl 30–49 mL/min) with dose-adjusted warfarin for stroke prevention in patients with nonvalvular atrial fibrillation [12].